[Our experience with lymphocytes activated against cancer: CTL cells].
Our group, thanks to the considerable help offered by prof. S. Fujimoto, Chief of the Immunologic Oncology Department of the Kochi Medical School (Japan), developed a method of "in vitro" activation of cytotoxic T lymphocytes (CTL), which are directed against tumour-specific antigens MHC-linked of the tumor cells. A protocol of specific immunotherapy based on the use of the CTL cells appropriately manipulated as therapeutic agents is our goal. The protocol recognizes five essential points: 1) retrieve and culture of tumor cells; 2) retrieve of T Lymphocytes; 3) induction of CTL cells; 4) assay of CTL activity; 5) reinfusion of the activated CTL cells to the patient.
Marcellino
L R
LR
Istituto di III Clinica Chirurgica Generale e Terapia Chirurgica, Università degli Studi La Sapienza, Roma.
Vinciguerra
M
M
Marcellino
M V
MV
Sessa
E
E
D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000627:therapeutic use; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000637:transplantation; D008213:Lymphocyte Activation / Q000276:immunology*; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000637:transplantation
D007376:Interleukin-2
La nostra esperienza con linfociti attivati contro il cancro: le cellule CTL.